The Irish life sciences sector experienced a robust mergers and acquisitions (M&A) landscape in 2025. After an initial slowdown attributed to geopolitical uncertainties in early 2025, M&A activity rebounded significantly in the latter half of the year, resulting in a moderate year-on-year increase in deal volume.
The life sciences and healthcare sector emerged as a dominant force, recording the highest reported deal value of any target sector in 2025. This surge was fueled by a combination of high-value strategic transactions and sustained foreign investment, underscoring Ireland’s continued appeal as a hub for innovation and development. Private equity and venture capital firms were particularly active, with their involvement accounting for 37% of deals in the sector and showing a substantial growth of 20%.
Key transactions that shaped the year included Mallinckrodt plc’s combination with Endo, Inc., Avadel Pharmaceuticals plc’s acquisition by Alkermes plc, and InvestIndustrial’s acquisition of DCC Healthcare. These deals highlight the dynamic nature of the sector and the significant capital flowing into Irish life sciences companies.
Looking ahead to 2026, the outlook for M&A in Ireland’s life sciences sector remains optimistic. Expectations point towards continued industry consolidation, sustained growth in private equity involvement, and strategic investments in critical physical infrastructure, such as manufacturing plants and production facilities. However, ongoing international political volatility and the evolving impact of Ireland’s new FDI screening regime are anticipated to be key factors influencing deal-making throughout the year.
About the Author
